{"entity":{"id":"european-urology","kind":"journal","name":"European Urology","aka":["Eur Urol"],"tldr":"European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.","summary":"Publishes the EAU guidelines, prostate-cancer screening and active-surveillance cohorts, PSMA PET and radioligand studies, and secondary analyses of the large phase 3 trials in bladder and kidney cancer. Hybrid access via Elsevier; sister titles include European Urology Oncology and European Urology Open Science.","asOf":"2026-09-09","links":[{"label":"EAU Guidelines","url":"https://uroweb.org/guidelines"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.europeanurology.com","issn":"0302-2838","scope":"urology","access":"hybrid","founded":1975,"impactFactor":{"value":25.2,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["European Urology","Eur Urol"],"society":"European Association of Urology"},"route":"/journals/european-urology/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"paper":[{"id":"paper-hugosson-eur-urol","kind":"paper","name":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","route":"/key-papers/paper-hugosson-eur-urol/"},{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/"},{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/"},{"id":"paper-johnson-mpmri-individual-foci-eur-urol-2019","kind":"paper","name":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","route":"/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/"},{"id":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","kind":"paper","name":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","route":"/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/"},{"id":"paper-boeve-eur-urol","kind":"paper","name":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","route":"/key-papers/paper-boeve-eur-urol/"},{"id":"paper-sylvester-eortc-risk-tables-eur-urol-2006","kind":"paper","name":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","route":"/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/"},{"id":"paper-eau-nmibc-guideline-eur-urol-2022","kind":"paper","name":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","route":"/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/"},{"id":"paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014","kind":"paper","name":"Overdiagnosis and overtreatment of prostate cancer","route":"/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/"},{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/"},{"id":"paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015","kind":"paper","name":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","route":"/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/"},{"id":"paper-who-2022-gu-moch-eur-urol-2022","kind":"paper","name":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","route":"/key-papers/paper-who-2022-gu-moch-eur-urol-2022/"},{"id":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","kind":"paper","name":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","route":"/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/"}],"person":[{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/"},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/"},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/"},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/"},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/"},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/"}]}}